Firm represents the clinical-stage biopharmaceutical company in the offering.
atai Life Sciences (NASDAQ: ATAI) (atai or Company), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, has announced the pricing of a registered underwritten offering of 26,190,477 common shares, at a price of US$2.10 per share. atai has granted the underwriter a 30-day option to purchase up to an additional 3,928,571 common shares. All common shares to be sold in the offering will be sold by atai.
Latham & Watkins advised atai Life Sciences in the offering, with a capital markets team led by New York partner Nathan Ajiashvili with associates Kaj Nielsen, Katie Byun, Adam Picker, and Skye Lee.
LEGAL DESIRE NEWSLETTER
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.
